BioLife Solutions Inc (BLFS)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $1.89B
Last updated: Nov 06, 2026 at 4:00 PM ET
BioLife Solutions Inc (BLFS) Financials: Revenue, Profit and Cash Flow
BioLife Solutions reported revenue of $96.21M for the fiscal year ended Dec 31, 2025, up 28.9% from the year before. That year, net income was -$4.59M with a net margin of -4.8%, operating cash flow was $20.11M and free cash flow was $10.64M. The quarter ended Jun 30, 2026 had revenue of $28.47M and net income of $45.10M.
Revenue and Margins
The operating margin was -17.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $8.23M, a compound annual rate of 31.4%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $96.21M | +28.9% | 64.6% | -17.3% | -4.8% |
| Dec 2024 | $74.65M | +9.7% | 67.1% | -6.0% | -27.0% |
| Dec 2023 | $68.02M | -10.8% | 60.7% | -25.3% | -100.0% |
| Dec 2022 | $76.24M | -36.0% | 61.5% | -7.8% | -183.4% |
| Dec 2021 | $119.16M | +147.8% | 31.1% | -29.5% | -7.5% |
| Dec 2020 | $48.09M | +75.7% | 57.1% | -13.0% | 4.1% |
| Dec 2019 | $27.37M | +38.6% | 68.0% | -0.8% | -6.1% |
| Dec 2018 | $19.74M | +79.1% | 68.5% | 18.5% | -126.7% |
| Dec 2017 | $11.02M | +34.0% | 61.2% | -9.6% | -22.8% |
| Dec 2016 | $8.23M | N/A | 58.1% | -59.0% | -97.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $96.21M | $74.65M | $68.02M | $76.24M | $119.16M | $48.09M | $27.37M | $19.74M | $11.02M | $8.23M |
| Cost of revenue | $34.10M | $24.55M | $26.70M | $29.33M | $82.11M | $20.65M | $8.76M | $6.22M | $4.28M | $3.45M |
| Gross profit | $62.12M | $50.10M | $41.32M | $46.91M | $37.05M | $27.44M | $18.61M | $13.53M | $6.75M | $4.78M |
| Research and development | $7.57M | $4.75M | $5.51M | $8.67M | $11.82M | $6.72M | $3.17M | $1.30M | $1.19M | $2.03M |
| Operating income | -$16.60M | -$4.48M | -$17.20M | -$5.92M | -$35.16M | -$6.24M | -$220.00K | $3.66M | -$1.06M | -$4.85M |
| Net income | -$4.59M | -$20.18M | -$68.00M | -$139.81M | -$8.91M | $1.98M | -$1.66M | -$25.00M | -$2.52M | -$8.04M |
| EBITDA | -$10.84M | $4.20M | $231.00K | $10.78M | -$22.01M | $2.43M | $14.40M | N/A | -$796.00K | -$4.39M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.47M | $27.50M | $18.79M | $28.07M | $23.44M | $22.05M | $15.11M | $21.39M | $19.71M | $18.43M | -$22.50M | $23.57M |
| Gross profit | $18.29M | $17.50M | $11.98M | $17.92M | $15.23M | $14.80M | $10.66M | $13.99M | $13.21M | $12.24M | $4.26M | $11.99M |
| Operating income | $1.70M | $27.00K | $1.35M | -$89.00K | -$16.13M | -$499.00K | $542.00K | -$418.00K | -$1.31M | -$3.29M | $22.50M | -$15.47M |
| Net income | $45.10M | $1.19M | $11.07M | $621.00K | -$15.84M | -$448.00K | $12.46M | -$1.70M | -$20.72M | -$10.22M | -$14.96M | -$29.13M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $5.00M by $28.04M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $405.88M | $399.49M | $412.71M | $450.23M | $554.29M | $234.83M | $92.82M | $45.47M | $12.14M | $7.93M |
| Current assets | $136.56M | $148.76M | $120.60M | $138.45M | $126.09M | $114.71M | $24.11M | $37.56M | $9.93M | $4.63M |
| Cash and equivalents | $33.04M | $91.54M | $27.90M | $19.44M | $69.86M | $90.40M | $6.45M | $30.66M | $6.66M | $1.41M |
| Total liabilities | $34.00M | $50.58M | $75.05M | $86.04M | $76.24M | $29.58M | $49.36M | $30.84M | $2.05M | $4.76M |
| Short-term debt | $5.00M | $10.94M | $6.29M | $3.95M | $5.99M | $3.25M | $377.00K | $0 | N/A | $2.84M |
| Long-term debt | N/A | $5.00M | $17.56M | $23.79M | $6.35M | $655.00K | N/A | N/A | $0 | $2.84M |
| Shareholder equity | $371.89M | $348.91M | $337.66M | $364.19M | $478.05M | $205.25M | $43.45M | $14.63M | $10.09M | $3.17M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $447.49M | $400.91M | $405.88M | $392.08M | $387.24M | $395.14M | $399.49M | $381.65M | $374.98M | $401.60M | $412.71M | $411.15M |
| Total liabilities | $27.49M | $28.68M | $34.00M | $38.34M | $40.09M | $42.52M | $50.58M | $56.19M | $53.53M | $68.20M | $75.05M | $79.14M |
| Cash and equivalents | $24.00M | $22.82M | $33.04M | $29.48M | $31.90M | $66.94M | $95.39M | $23.98M | $22.01M | $29.69M | $27.90M | $19.23M |
| Shareholder equity | $420.00M | $372.23M | $371.89M | $353.74M | $347.15M | $352.62M | $348.91M | $325.46M | $321.44M | $333.40M | $337.66M | $332.02M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 52.9% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $20.11M | $8.43M | -$12.50M | -$8.49M | -$4.59M | $6.64M | $1.21M | $2.35M | $605.00K | -$4.33M |
| Capital expenditures | $9.48M | $3.23M | $6.38M | $10.38M | $8.38M | $1.96M | $675.00K | $500.00K | $144.00K | $1.26M |
| Free cash flow | $10.64M | $5.20M | -$18.88M | -$18.87M | -$12.98M | $4.68M | $538.00K | $1.85M | $461.00K | -$5.58M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $436.00K | $106.00K | $0 |
| Share repurchases | N/A | N/A | N/A | $131.00K | $145.00K | $6.20M | $0 | N/A | $52.00K | $111.74K |
| Investing cash flow | -$71.54M | $58.30M | $17.84M | -$58.12M | -$13.19M | -$24.71M | -$27.02M | -$6.50M | -$144.00K | $392.79K |
| Financing cash flow | -$10.92M | -$6.78M | $10.59M | $16.32M | -$2.78M | $102.08M | $1.60M | $28.15M | $4.80M | $3.17M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $6.35M | -$491.00K | $4.92M | $6.10M | $7.37M | $1.73M | $1.65M | $4.80M | $6.46M | -$4.47M | $2.31M | -$4.38M |
| Capital expenditures | $1.04M | $167.00K | $4.26M | $3.30M | $1.74M | $175.00K | $762.00K | $1.11M | $995.00K | $356.00K | $981.00K | $1.50M |
| Free cash flow | $5.30M | -$658.00K | $658.00K | $2.80M | $5.63M | $1.55M | $883.00K | $3.69M | $5.46M | -$4.83M | $1.33M | -$5.88M |
Frequently Asked Questions About BLFS
What is BioLife Solutions' annual revenue?
BioLife Solutions reported revenue of $96.21M for the fiscal year ended Dec 31, 2025.
How fast is BioLife Solutions' revenue growing?
Revenue was up 28.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.1%.
Is BioLife Solutions profitable?
No. BioLife Solutions reported net income of -$4.59M for the fiscal year ended Dec 31, 2025, with a net margin of -4.8%.
How much free cash flow does BLFS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $20.11M minus capital expenditures of $9.48M produced free cash flow of $10.64M.
How much debt does BioLife Solutions have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $5.00M and cash and equivalents of $33.04M.
BLFS pages: Overview, Financials, Government Contracts